Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-TechneFRA:TE1 +0.29%88 Interest Coverage is 44.74 as of Jun. 2026, which is 142% above its 10-year median of 18.52. GuruFocus rates FRA:TE1 with a GF Score™ of 88/100 and a GF Value™ of €60.77 (Fairly Valued). The stock has 7 warning signs investors should review. Among 368 Biotechnology companies, Bio-Techne ranks worse than 63.04% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Bio-Techne's
Operating Income
for the
three
months ended in Jun. 2026 was €82 Mil. Bio-Techne's Interest Expense for the
three
months ended in Jun. 2026 was €-2 Mil.
Bio-Techne's interest coverage for the quarter that ended in Jun. 2026 was 44.74.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Bio-Techne's Interest Coverage or its related term are showing as below:
FRA:TE1'
s Interest Coverage Range Over the Past 10 Years
Min: 6.78 Med: 18.52 Max: 28.53
Current: 28.31
FRA:TE1's Interest Coverage is ranked worse than 63.04% of 368
companies
in the Biotechnology industry
Industry Median: 98.255
vs FRA:TE1: 28.31
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Bio-Techne Interest Coverage Related Terms
Bio-Techne Interest Coverage Historical Data
* Premium members only.
The historical data trend for Bio-Techne's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:TE1 vs SMMT, HALO, ARWR: Interest Coverage Comparison
For the Biotechnology subindustry, Bio-Techne's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (FRA:TE1) has a Interest Coverage of 44.74 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bio-Techne and its competitors. This is 142% above median its historical median of 18.52. Over the past decade, Bio-Techne's Interest Coverage has ranged from 6.78 to 28.53. According to the industry distribution chart, Bio-Techne ranks #232 out of 368 companies in the Biotechnology industry, placing it in the top 63%.
Is Bio-Techne's Interest Coverage too high?
Bio-Techne's current Interest Coverage of 44.74 is 142% above median its 10-year median of 18.52. Over the past 10 years, this metric has ranged from a low of 6.78 to a high of 28.53. The Biotechnology industry median Interest Coverage is 98.26. Bio-Techne's value of 44.74 is 54.5% below this industry median. Based on the distribution chart, Bio-Techne ranks #232 out of 368 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bio-Techne has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Interest Coverage compare to SMMT and HALO?
According to the Biotechnology industry distribution chart, Bio-Techne ranks #232 out of 368 companies for Interest Coverage. This places Bio-Techne in the lower half of its industry. The industry median Interest Coverage is 98.26. Bio-Techne's value of 44.74 is 54.5% below this benchmark. Historically, Bio-Techne's own Interest Coverage has ranged from 6.78 to 28.53 over the past decade. While the company's 10-year median is 18.52 vs. the industry median of 98.26, Bio-Techne has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 98.26, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Techne's current Interest Coverage of 44.74 is 54.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bio-Techne and its competitors. For the Biotechnology industry, the median Interest Coverage is 98.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Techne's current Interest Coverage is 44.74, which is 142% above median its own 10-year median of 18.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (FRA:TE1) is currently considered Fairly Valued. The stock's GF Value™ is €60.77, compared to a current price of €61.86 — trading 1.8% above its estimated fair value. The current Interest Coverage is 44.74, which is 142% above median its 10-year median of 18.52 and 54.5% below the Biotechnology industry median of 98.26. Bio-Techne's overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Bio-Techne (FRA:TE1), the current Interest Coverage is 44.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Techne (FRA:TE1) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Techne stock appears to be overvalued.
The current stock price of €61.86 is trading 1.8% above its estimated GF Value™ of €60.77.
GuruFocus considers Bio-Techne to be Fairly Valued.
Key valuation signals for FRA:TE1:
Interest Coverage: 44.74 (142% above median its 10-year median of 18.52)
GF Value™: €60.77 vs. price of €61.86 (1.8% above fair value)
Industry Position: 54.5% below the Biotechnology median (#232 of 368)
No single metric tells the full story. See the FRA:TE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
88GF Score
Get the complete analysis for FRA:TE1
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TE1 has been successfully added to your 
